The Reflux Company Concludes Oversubscribed Seed Round – Appoints MAAB Group as Advisory Service for Chinese Market

BREMERTON, WA, UNITED STATES, April 6, 2026

The Reflux Company, the only global firm devoted exclusively to the diagnosis and treatment of reflux, today announced the appointment of MAAB Group as its official Advisory service for commercial activity in Asia with a focus on China, as well as MAAB’s participation in its Seed Round. The agreement covers distribution, market access, business development, and additional fundraising, according to Thomas Ball, PhD, Founder and CEO of the Reflux Company.
“We already have a strong footprint in the US and Latin America,” Ball notes, “and a growing one in Europe. This agreement with MAAB, supported by their investment, will enable strong regional growth throughout Asia but especially in the vibrant Chinese market.”
The Reflux Company’s products include Dx-pH™, the only sensor available to test both liquid and aerosolized pH, widely used by ENTs and other physicians to diagnose oropharyngeal reflux. For treatment, the company offers Stretta®, a minimally invasive outpatient procedure that provides an alternative to reflux-related surgery and implants. Other products include the direct-to-consumer Reflux Band® and PepsinCheck by Peptest®.
“Beyond capital, MAAB will bring us strong commercialization capabilities, particularly in complex and high-growth markets such as China,” according to Ball. “MAAB’s team combines deep expertise in regulatory strategy, market access, cross-border partnerships, and is well positioned to support the successful introduction and expansion of innovative life science products like ours, accelerating our market entrance.”
“We believe The Reflux Company is uniquely positioned to grow in the global market,” says Alex Lou, Managing Director of MAAB Group. “There are currently over 1 billion patients globally in need of diagnosis and treatment, and The Reflux Company’s portfolio offers physicians a compelling combination of tools for both.”
The MAAB Group investment represents one element of a $1M seed round raised by The Reflux Company. The round is currently fully subscribed and will close in early Q2.

ABOUT THE REFLUX COMPANY
The Reflux Company is building a unified platform for a full range of reflux related medical devices, software, and services for Laryngopharyngeal Reflux (LPR) and Gastroesophageal Reflux Disease (GERD). The company’s products serve multiple medical specialties involved in the diagnosis and treatment of LPR and GERD, as well as providing direct-to-consumer solutions for patients. Founded in 2025 by Thomas Ball, Ph.D., The Reflux Company’s intellectual property portfolio includes mature, in-market products as well as an innovative pipeline, and benefits further from the global sales and distribution experience of its founder and key investors.

ABOUT MAAB GROUP
MAAB Group is a boutique investment and commercialisation platform founded by pharmaceutical industry veterans. The company specialises in the cross-border licensing and trade of innovative medical technologies, with a portfolio spanning reflux diagnostics and treatments, neurological AI tools, and next-generation probiotics and microbiome-based therapies.

Founded in 2011 and originally incorporated in Hong Kong, MAAB is now headquartered in New Zealand, with operational presence in Mainland China, the United Kingdom, and Denmark. MAAB partners with innovative companies worldwide to unlock market opportunities through smart localisation, regulatory strategy, and commercial partnership.” The Reflux Company marks MAAB’s first US engagement.